Hi everyone, below is a link to a new paper published in the Blood Journal August 9 by Dr's Young and Scheinberg at the NIH.
http://bloodjournal.hematologylibrar...1185.full.html
The paper contains really good current information on AA treatments and strategies from the 2 leading AA experts.
I thought this excerpt, towards the end of the paper & especially the bold text, was particularly interesting because I've seen a lot of postings on Marrowforums where it looks like Dr's have equated success of AA treatment or progress based on celularity of the bone marrow, but this excerpt doesn't seem to necessarily support that theory.
"How we follow SAA long term"
"Responders should be followed for late complications of relapse and clonal evolution (Figure 2). We assess for bone marrow morphology and especially karyotype at 6 and 12 months after treatment and then yearly to monitor for evolution.
A hypocellular marrow should not be equated with persistent SAA or relapse in the setting of improving blood counts, as marrow cellularity often does not correlate with blood counts. Blood counts, not marrow cellularity, should guide management."
Best, Dena